UBS Group’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $65.2K | Sell |
115,200
-72
| -0.1% | -$49 | ﹤0.01% | 7224 |
|
|
2025
Q4 | $73.7K | Buy |
115,272
+69
| +0.1% | +$53 | ﹤0.01% | 7048 |
|
|
2025
Q3 | $108K | Sell |
115,203
-7,129
| -6% | -$7.02K | ﹤0.01% | 7066 |
|
|
2025
Q2 | $157K | Buy |
122,332
+7,132
| +6% | +$7.16K | ﹤0.01% | 6894 |
|
|
2025
Q1 | $115K | Sell |
115,200
-29,725
| -21% | -$31.3K | ﹤0.01% | 6946 |
|
|
2024
Q4 | $132K | Buy |
144,925
+142,354
| +5,537% | +$140K | ﹤0.01% | 6704 |
|
|
2024
Q3 | $3.86K | Buy |
2,571
+714
| +38% | +$783 | ﹤0.01% | 8213 |
|
|
2024
Q2 | $1.3K | Buy |
1,857
+1,800
| +3,158% | +$1.56K | ﹤0.01% | 8598 |
|
|
2024
Q1 | $54 | Sell |
57
-2,904
| -98% | -$2.83K | ﹤0.01% | 8918 |
|
|
2023
Q4 | $3.29K | Buy |
2,961
+2,764
| +1,403% | +$4.11K | ﹤0.01% | 7993 |
|
|
2023
Q3 | $370 | Sell |
197
-928
| -82% | -$2.66K | ﹤0.01% | 8544 |
|
|
2023
Q2 | $4.04K | Buy |
1,125
+645
| +134% | +$2.04K | ﹤0.01% | 7577 |
|
|
2023
Q1 | $1.62K | Sell |
480
-3,066
| -86% | -$9.2K | ﹤0.01% | 8692 |
|
|
2022
Q4 | $5.5K | Sell |
3,546
-2,112
| -37% | -$3.13K | ﹤0.01% | 9171 |
|
|
2022
Q3 | $7K | Buy |
5,658
+5,200
| +1,135% | +$10.2K | ﹤0.01% | 8857 |
|
|
2022
Q2 | $1K | Sell |
458
-2,735
| -86% | -$6.28K | ﹤0.01% | 9841 |
|
|
2022
Q1 | $10K | Sell |
3,193
-8,060
| -72% | -$28.9K | ﹤0.01% | 8403 |
|
|
2021
Q4 | $48K | Buy |
11,253
+9,654
| +604% | +$54.2K | ﹤0.01% | 6929 |
|
|
2021
Q3 | $13K | Sell |
1,599
-1,819
| -53% | -$14.8K | ﹤0.01% | 7658 |
|
|
2021
Q2 | $26K | Sell |
3,418
-4,164
| -55% | -$35.1K | ﹤0.01% | 7070 |
|
|
2021
Q1 | $66K | Sell |
7,582
-241
| -3% | -$2.3K | ﹤0.01% | 6278 |
|
|
2020
Q4 | $62K | Buy |
7,823
+7,517
| +2,457% | +$62.9K | ﹤0.01% | 5994 |
|
|
2020
Q3 | $2K | Sell |
306
-13,176
| -98% | -$119K | ﹤0.01% | 7643 |
|
|
2020
Q2 | $133K | Sell |
13,482
-15,169
| -53% | -$139K | ﹤0.01% | 5095 |
|
|
2020
Q1 | $221K | Sell |
28,651
-14,364
| -33% | -$72.5K | ﹤0.01% | 4645 |
|
|
2019
Q4 | $166K | Buy |
43,015
+18,326
| +74% | +$79.9K | ﹤0.01% | 5716 |
|
|
2019
Q3 | $124K | Sell |
24,689
-23,030
| -48% | -$134K | ﹤0.01% | 5623 |
|
|
2019
Q2 | $315K | Buy |
47,719
+12,579
| +36% | +$86.4K | ﹤0.01% | 4624 |
|
|
2019
Q1 | $266K | Buy |
35,140
+3,907
| +13% | +$30.4K | ﹤0.01% | 4435 |
|
|
2018
Q4 | $253K | Buy |
31,233
+8,108
| +35% | +$80.5K | ﹤0.01% | 4772 |
|
|
2018
Q3 | $299K | Sell |
23,125
-12,386
| -35% | -$155K | ﹤0.01% | 4754 |
|
|
2018
Q2 | $405K | Buy |
35,511
+35,415
| +36,891% | +$335K | ﹤0.01% | 4470 |
|
|
2018
Q1 | $1K | Sell |
96
-1,399
| -94% | -$10.6K | ﹤0.01% | 7630 |
|
|
2017
Q4 | $10K | Buy |
+1,495
| New | +$9.51K | ﹤0.01% | 7007 |
|
|
2017
Q2 | – | Sell |
-94
| Closed | – | – | 7715 |
|
|
2017
Q1 | $0 | Sell |
94
-3,806
| -98% | -$21.3K | ﹤0.01% | 7689 |
|
|
2016
Q4 | $21K | Buy |
3,900
+3,256
| +506% | +$17.8K | ﹤0.01% | 6482 |
|
|
2016
Q3 | $4K | Sell |
644
-2,438
| -79% | -$12.7K | ﹤0.01% | 7192 |
|
|
2016
Q2 | $14K | Buy |
+3,082
| New | +$13.4K | ﹤0.01% | 6563 |
|
|
2015
Q4 | – | Sell |
-2,256
| Closed | -$14K | – | 8372 |
|
|
2015
Q3 | $14K | Sell |
2,256
-753
| -25% | -$5.02K | ﹤0.01% | 7008 |
|
|
2015
Q2 | $18K | Buy |
3,009
+995
| +49% | +$6.77K | ﹤0.01% | 6963 |
|
|
2015
Q1 | $27K | Buy |
+2,014
| New | +$20.7K | ﹤0.01% | 6654 |
|
Other funds holding CTSO
AC
VCM
SC
CM
SIG
VFT
UBS Group's CTSO Position: Q1 2026 in Review
UBS Group reduced its Cytosorbents Corp (CTSO) stake by 0.06% in Q1 2026, selling an estimated $49 and leaving 115,200 shares worth $65.2K. The position accounts for ﹤0.01% of the portfolio, ranked #7224.
UBS Group first reported a position in CTSO in Q1 2015 and has held it in 41 quarters since. The position peaked at $405K in Q2 2018. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.
- UBS Group held 115,200 shares of Cytosorbents Corp worth $65.2K as of Q1 2026.
- UBS Group sold 72 Cytosorbents Corp shares in Q1 2026, an estimated $49.
- Cytosorbents Corp made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7224 holding.
- UBS Group first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 41 quarters since.
- UBS Group's Cytosorbents Corp position peaked at $405K in Q2 2018.
- 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.